马后炮， 技术上前面那个gap down 就该小心了，起码除掉一部分
基本面上 Akorn (AKRX -14.4%) slumps on double normal volume in response to
Actavis' (ACT -1.2%) after hours announcement of its U.S. launch of a
generic version of Fougera's Temovate (clobetasol cream 0.05%) for the
relief of inflammatory and pruritic dermatoses. Akorn's generic version was
one of its top sellers last quarter.
l*********m 发帖数: 446
5
受教了
was
【在 l*********t 的大作中提到】 : 马后炮， 技术上前面那个gap down 就该小心了，起码除掉一部分 : 基本面上 Akorn (AKRX -14.4%) slumps on double normal volume in response to : Actavis' (ACT -1.2%) after hours announcement of its U.S. launch of a : generic version of Fougera's Temovate (clobetasol cream 0.05%) for the : relief of inflammatory and pruritic dermatoses. Akorn's generic version was : one of its top sellers last quarter.
